浙江医药：关于拟筹划控股子公司分拆上市的提示性公告

Core Viewpoint - Zhejiang Medicine announced plans to spin off its subsidiary, Zhejiang Xima Biotechnology Co., Ltd., for a public listing on the Hong Kong Stock Exchange [1] Group 1 - The company's board meeting is scheduled for November 26, 2025, to review the proposal for the spin-off [1] - The spin-off aims to enhance the subsidiary's market presence and financial independence [1]